Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

Congratulations to our longstanding member Dr. Hans Wildiers for receiving the B.J. Kennedy Geriatric Oncology Award at the 2023 ASCO Annual Meeting.

Created in 2007 in honour of B.J. Kennedy, MD, this award recognises an ASCO member who has made outstanding contributions to the research, diagnosis, and treatment of cancer in the elderly, and in bringing an understanding of geriatric oncology to fellows and junior faculty.

During the Award Lecture (session available on-demand for participants), Dr. Wildiers presented a session titled “Looking Back and Moving Forward” where he focused on the achievements in the field of geriatric oncology and the work that is still needed to improve the care of older patients with cancer.

During his presentation, he thanked organisations like EORTC, which have strongly supported geriatric oncology research in the last years.

“It is my great honour to receive this year’s the B.J. Kennedy Geriatric Oncology Award. […] Within the EORTC, we had a lot of discussions on the optimal trial design for older patients with cancer.”

– Dr. Hans Wildiers

Dr. Wildiers is a medical oncologist dedicated to breast cancer research. He has served as a staff member in the Department of Medical Oncology at the University Hospital Leuven, Belgium, since 2004. Since 2015, he has been the coordinator of the Leuven Multidisciplinary Breast Center. He has also been the coordinator of several academic studies in the field of breast cancer and geriatric oncology and is the author of more than 350 peer-reviewed papers. He has been active on the Board of the International Society of Geriatric Oncology for many years and served as the organisation’s president from 2018 to 2020. From 2009 to 2015, he chaired the Cancer in the Elderly Task Force of the European Organisation for Research and Treatment of Cancer (EORTC).

More information here.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023